SB239063 | CAS#193551-21-2 | p38MAPK inhibitor

MedKoo Cat#: 406337 | Name: SB239063

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-alpha production (IC(50) values = 0.12 and 0.35 microM, respectively). SB 239063 may be useful for the treatment of asthma and other inflammatory disorders.

Chemical Structure

SB239063

CAS#193551-21-2

Theoretical Analysis

MedKoo Cat#: 406337

Name: SB239063

CAS#: 193551-21-2

Chemical Formula: C20H21FN4O2

Exact Mass: 368.1649

Molecular Weight: 368.40

Elemental Analysis: C, 65.20; H, 5.75; F, 5.16; N, 15.21; O, 8.69

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 275.00	2 Weeks
50mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SB239063; SB239063; SB 239063.

IUPAC/Chemical Name

(1r,4r)-4-(4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)-1H-imidazol-1-yl)cyclohexanol

InChi Key

ZQUSFAUAYSEREK-WKILWMFISA-N

InChi Code

InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16-

SMILES Code

O[C@H]1CC[C@H](N2C(C3=NC(OC)=NC=C3)=C(C4=CC=C(F)C=C4)N=C2)CC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition

0 Â– 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

Solubility

Soluble in DMSO, not soluble in water.

Shelf Life

>2 years if stored properly.

Drug Formulation

Stock solution storage:

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SB239063 had an IC50 of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB239063 inhibited interleukin-1 and tumor necrosis factor-alpha production (IC50 values = 0.12 and 0.35 microM, respectively).

In vitro activity:

Anti-inflammatory treatment with SB239063 in organotypic hippocampal slice cultures reduced cell death, inflammation and microglia activation and enhanced the oxygen-glucose deprivation-induced neurogenesis in the posterior periventricle. Levels of cytokine IL-1beta were reduced by 84% after treatment with SB239063 but IL-6 and TNF-alpha were not affected. Reference: Eur J Pharmacol. 2008 Sep 11;592(1-3):55-61. https://pubmed.ncbi.nlm.nih.gov/18638472/

In vivo activity:

Acute treatment with SB239063 may have ameliorating effects in early changes of LPS-induced sickness behavior and alteration in the peripheral cytokines/hormones. LPS increased Interleukin (IL)-1β, IL-6, IL-10, Granulocyte-Macrophage-Colony Stimulating Factor, Interferon-γ, and C-reactive-protein levels, but not when preceded by SB239063. LPS significantly decreased growth-hormone and Prolactin, which was attenuated by SB-239063. Reference: Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. https://pubmed.ncbi.nlm.nih.gov/21545800/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	27.14
	DMSO	16.0	43.43
	Ethanol	0.3	0.69

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 368.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Strassburger M, Braun H, Reymann KG. Anti-inflammatory treatment with the p38 mitogen-activated protein kinase inhibitor SB239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen-glucose-deprived hippocampal slice cultures. Eur J Pharmacol. 2008 Sep 11;592(1-3):55-61. doi: 10.1016/j.ejphar.2008.06.099. Epub 2008 Jul 3. PMID: 18638472. 2. Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur J Pharmacol. 2002 Jun 28;447(1):37-42. doi: 10.1016/s0014-2999(02)01890-3. PMID: 12106800. 3. Huang B, Wang J, Zhang X, Xie Z, Wu H, Liu J, Jie Z, Zhao X, Qin A, Fan S, Chen J, Zhao F. Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice. Front Pharmacol. 2019 Aug 15;10:900. doi: 10.3389/fphar.2019.00900. PMID: 31474861; PMCID: PMC6704231. 4. Bison S, Razzoli M, Arban R, Michielin F, Bertani S, Carboni L. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. doi: 10.1016/j.ejphar.2011.04.020. Epub 2011 Apr 27. PMID: 21545800.

In vitro protocol:

In vivo protocol:

1. Huang B, Wang J, Zhang X, Xie Z, Wu H, Liu J, Jie Z, Zhao X, Qin A, Fan S, Chen J, Zhao F. Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice. Front Pharmacol. 2019 Aug 15;10:900. doi: 10.3389/fphar.2019.00900. PMID: 31474861; PMCID: PMC6704231. 2. Bison S, Razzoli M, Arban R, Michielin F, Bertani S, Carboni L. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. doi: 10.1016/j.ejphar.2011.04.020. Epub 2011 Apr 27. PMID: 21545800.

1: Bison S, Razzoli M, Arban R, Michielin F, Bertani S, Carboni L. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. doi: 10.1016/j.ejphar.2011.04.020. Epub 2011 Apr 27. PubMed PMID: 21545800. 2: Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur J Pharmacol. 2002 Jun 28;447(1):37-42. PubMed PMID: 12106800. 3: Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44. PubMed PMID: 11683250. 4: Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. 2001 Feb 16;892(1):70-7. PubMed PMID: 11172750. 5: Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther. 2001 Feb;296(2):312-21. PubMed PMID: 11160612. 6: Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902. PubMed PMID: 11053025. 7: Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000 Apr;293(1):281-8. PubMed PMID: 10734180.